Secondary resistance to idelalisib is characterized by upregulation of IGF1R rather than by MAPK/ERK pathway mutationsShow others and affiliations
2022 (English)In: Blood, ISSN 0006-4971, E-ISSN 1528-0020, Vol. 139, no 22, p. 3340-3344Article in journal, Letter (Other academic) Published
Place, publisher, year, edition, pages
American Society of Hematology American Society of Hematology, 2022. Vol. 139, no 22, p. 3340-3344
National Category
Hematology
Identifiers
URN: urn:nbn:se:uu:diva-480120DOI: 10.1182/blood.2021014550ISI: 000810967400013PubMedID: 35377939OAI: oai:DiVA.org:uu-480120DiVA, id: diva2:1681605
Funder
Swedish Research CouncilKnut and Alice Wallenberg FoundationSwedish Cancer SocietyKarolinska Institute2022-07-072022-07-072024-01-15Bibliographically approved